bioAffinity Announces Upcoming Departure of Two Board Directors

bioAffinity Technologies, Inc. ( (BIAF) ) has shared an update.

bioAffinity Technologies, Inc. disclosed that on March 5, 2026, directors Robert Anderson and Roby Joyce informed the Board they will not stand for re-election when their current terms end at the 2026 Annual Meeting of Stockholders, scheduled for April 30, 2026. The company said their decisions were not due to any disagreements over operations, policies or practices, signaling an orderly board transition rather than a response to internal conflict, which should help reassure investors and other stakeholders about governance stability.

The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc., a Delaware corporation, operates in the biotechnology sector, though the specific products or services it offers are not detailed in the announcement. The company is governed by a Board of Directors whose composition is subject to change at its Annual Meeting of Stockholders, where directors’ terms are set to expire and potential successors may be elected.

Average Trading Volume: 145,762

Technical Sentiment Signal: Sell

Current Market Cap: $4.63M

See more insights into BIAF stock on TipRanks’ Stock Analysis page.